DUSP16 and Burkitt lymphoma: It would be of obvious interest to analyse the expression and epigenetic status of DUSP16 in relapsed BL (at which time there are few active chemotherapeutic options) to determine whether changes in methylation in the DUSP16 CpG island occur with acquisition of clinical drug resistance.